Should combined endocrine therapy with targeted agents now be the standard of care for ER+ metastatic breast cancer?
Yes
Date
09 Oct 2016Session
Should combined endocrine therapy with targeted agents now be the standard of care for ER+ metastatic breast cancer?Presenters
Angelo di LeoAuthors
A. di LeoAuthor affiliations
- Oncology- Istituto Toscano Tumori, Ospedale di Prato Sandro Pitigliani Med. Oncology Unit, 59100 - Prato/IT
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Second vote and conclusions
Presenter: Michael Gnant
Session: Should combined endocrine therapy with targeted agents now be the standard of care for ER+ metastatic breast cancer?
Resources:
Slides
Webcast
Introduction and first vote
Presenter: Michael Gnant
Session: Should combined endocrine therapy with targeted agents now be the standard of care for ER+ metastatic breast cancer?
Resources:
Slides
Webcast